For Health Plans, The Road to F6 Compliance Starts Now. Here’s Where to Begin.
Major Changes Could Create Risks
The National Council for Prescription Drug Programs (NCPDP) F6 standard introduces 200 new, 150 modified, and 50 removed data fields, requiring health plans to make significant system and process changes. The most frequently discussed upgrade is the expansion of the 6-digit BIN to an 8-digit Issuer Identification Number (IIN). Other fields are designed to provide more clinical detail, a change the industry has been asking for. These four areas deserve close attention from health plans to avoid costly mistakes.
1. Coordination of Benefits (COB)
F6 adds multiple new dimensions to COB communications, including new and revised fields for copay, coinsurance, patient pay, tax percentage, and regulatory fees. The changes are intended to improve processing by supporting multi-payer scenarios common with specialty drugs, including manufacturer co-pay cards and patient assistance programs. Because these changes affect accumulators, any missteps can lead to adjudication and reimbursement errors, such as failing to recognize a primary payer, overpaying a secondary payer, or overpayments by members.
2. Order of processing
The new B98-34 field (Reconciliation ID) provides a means to identify subsequent transactions, while the new 338-5C field (Other Payer Coverage Type) identifies the order of processing. As a result, health plans could face increased claims reversals and reprocessing if transactions for primary, secondary, and other payers are not sequential.
3. Formulary alternatives
New fields such as D43-PZ (Formulary Alt Reason Code) indicate why the formulary alternative was returned. These changes will provide more clinical and formulary information up front to point-of-sale providers. However, if not deployed correctly, the D43-PZ field could increase provider abrasion due to greater back-and-forth with prescribers on requested alternatives.
4. Clinical optimization
Several new fields for identifying controlled substances, more precise quantity details, and differentiation between multiple dispensing and refills will help increase safety. Misclassification of controlled substance fills, however, could lead to the use of outdated drug review strategies, potentially exposing plans to noncompliance with state and federal drug monitoring requirements.
Turn F6 Transition Risks into Opportunities
The total industry cost for F6 adoption is estimated to be more than $380 million, with PBMs bearing most of the cost. Yet while those costs are high, payer organizations that get the transition right will reap many benefits.
Just one example: With real-time information exchange, plans will be able to switch high-cost specialty drugs to preferred alternatives at the point of sale. This one change could potentially save plans up to $100,000 a year on certain therapies.
Additionally, plans that leverage the expanded COB fields can improve member satisfaction by reducing or eliminating the burden of patients receiving multiple bills from different clinical and pharmacy providers. Tighter connections among health plans, PBMs, and POS pharmacies will make pharmacists’ jobs easier while also easing prior authorization burdens across the board.
Start the Transition Early
Payer organizations should begin mapping their D.0 to F6 transition strategies now so they are fully prepared for the April 2028 deadline.
The best first step is to carefully review the pharmacy data trail and pinpoint all the areas it influences. Commercial plans will need to weigh the impact of new and revised COB fields on accumulators. Medicaid and other government-sponsored plans must ensure compliance with both the new F6 standards and any state-specific guidance regarding pharmacy data exchange.
Once plans assess all areas of impact, identify any gaps. These could include data silos or legacy systems that hinder efficient data exchange. They could also include vulnerabilities related to vendor contracts, payer sheets, or member-facing materials. By starting 18 months in advance (October 2026), plans will have the time to identify such gaps and develop an organization-wide strategy to address them.
Close coordination with PBM partners and other vendors is crucial to a smooth transition. Develop a mutual timeline to determine when D.0 and F6 will run in parallel and when the full transition to F6 will be complete. Doing so will help plans avoid the potential financial and member experience implications that could occur if a PBM transitions to F6 before the plan is ready, and vice versa.
Achieve F6 Compliance with a Trusted Partner
With so many moving parts, many plans will need outside experts to navigate the D.0 to F6 journey. AArete supports payer organizations at every step of the transition. Count on our health plan consultants to:
Rapidly assess technology, vendor operations, and pharmacy reporting. We will educate stakeholders on key F6 provisions and potential risks and conduct stakeholder interviews to assess business, operational, and technical readiness.
Identify operational and technological gaps. We will conduct a gap analysis and distill our findings into a high-level implementation roadmap that outlines any staffing and systems investment requirements.
Support implementation. AArete’s experts can manage the implementation plan, secure cross-functional stakeholder support, and facilitate cross-departmental coordination during each phase of the transition.
Act Now to Meet the April 2028 F6 Deadline
The NCPDP’s timeline calls for organizations to begin formal and informal F6 testing and remediation in Q4 2026, with transition to full use starting in the second half of 2027. Plans that begin the transition now and enlist the help of a trusted partner will meet the expected timelines and improve pharmacy data exchange, benefitting their staff, providers, members, and partners. Let AArete’s experts help ensure you are well-positioned ahead of these milestones.
Learn more about AArete’s Pharmacy Solutions.
